LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.21 -6.62%

-$0.42 today

Market cap
$100.86M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.62M

Average 0.89M

LENZ Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

LENZ Therapeutics, Inc.NASDAQ: LENZ

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 31.35M shares rose 13.9% year over year, ahead of the +10.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +54.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +13.9% holds above the trailing-twelve-month pace of +10.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
31.35M+0.9% QoQ
Last fiscal yearDec 2025
28.81M+35.4% YoY
LTMMar 2026
29.76M+10.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.9%——
1 year+35.4%——
3-year CAGR+54.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
28.81M USD
Year-over-year change
+35.4%
4-year CAGR
+36.6%

Weighted Avg Shares vs competitors

How LENZ compares with its peers on the latest reported figures

  • LENZ's LTM Mar 2026 weighted avg shares of 29.76M shares is the lowest of the 11 companies compared; the peer median is 123.71M shares.
  • Its year-over-year change of +10.4% is the 5th highest of 11, against a peer median of +2.4%.
  • Over three fiscal years its annual growth of +54.3% compares with a peer median of +12.9%.
LENZ Competitors Peer median
Weighted Avg Shares for LENZ and competitors
Company Period LTM YoY 3-year CAGR
GERNGeron CorporationLTM Mar 2026667.45M +1.6%+20.5%
SVRASavara Inc.LTM Mar 2026227.14M +12.3%+13.3%
ABUSArbutus Biopharma CorporationLTM Mar 2026192.17M +2.0%+8.3%
PRMEPrime Medicine, Inc.LTM Mar 2026153.89M +26.0%+15.2%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026146.04M +2.7%+3.3%
RZLTRezolute, Inc.LTM Mar 2026101.37M +55.6%+61.0%
SPRYARS Pharmaceuticals, Inc.LTM Mar 202698.76M +1.3%+35.1%
GHRSGH Research PLCLTM Mar 202662.03M +15.9%+5.5%
TYRATyra Biosciences, Inc.LTM Mar 202660.14M +2.0%+12.5%
NBTXNanobiotix S.A.FY202547.82M +1.2%+11.1%
LENZLENZ Therapeutics, Inc.LTM Mar 202629.76M +10.4%+54.3%
Peer median (excluding LENZ) 123.71M+2.4%+12.9%

Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue015M0019.09M
Cost of Revenue734K0058K705K
Gross Profit(734K)15M0(58K)18.38M
Gross Margin—100.0%——96.3%
Research & Development37.93M21.13M59.5M29.8M18.67M
Selling, General & Admin21.78M4.36M12.93M28.75M90.85M
Operating Expenses59.71M25.48M72.43M58.55M109.52M
Depreciation & Amortization734K8K15K58K287K
EBITDA(70.03M)(10.46M)(70.13M)(49.71M)(81.34M)
EBITDA Margin—-69.7%——-426.1%
Operating Income(60.44M)(10.48M)(72.43M)(58.61M)(91.14M)
Operating Margin—-69.9%——-477.5%
Interest Income002.19M8.55M9.76M
Interest Expense00000
Other Income / Expenses(10.32M)19K2.28M8.84M9.51M
Income Before Tax(70.76M)(10.46M)(70.15M)(49.77M)(81.63M)
Pre-Tax Margin—-69.8%——-427.6%
Income Tax Expense0347K(179K)1K502K
Net Income(70.76M)(10.81M)(69.97M)(49.77M)(82.13M)
Net Margin—-72.1%——-430.3%
EPS (Basic)(8.54)(12.89)(15.30)(2.34)(2.85)
EPS (Diluted)(8.54)(12.89)(15.30)(2.34)(2.85)
Weighted Avg Shares8.29M7.84M8.15M21.28M28.81M
Weighted Avg Shares (Diluted)8.29M7.84M8.15M21.28M28.81M

LENZ Therapeutics, Inc.

NASDAQ:LENZ

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.